AJR Am J Roentgenol. 2015 Jul;205(1):85-9. doi: 10.2214/AJR.14.13835.
Shampain KL1, Davenport MS1,2, Cohan RH1, Goodsitt MM1, Ellis JH1, Platt JF1.
OBJECTIVE: The purpose of this study was to assess the effect of model-based iterative reconstruction (MBIR) on CT number measurements within small (10-29 mm) low-attenuation renal masses.
MATERIALS AND METHODS: One hundred 10- to 29-mm exophytic or endophytic low-attenuation renal lesions imaged with CT (unenhanced and nephrographic [100 seconds] phases, 120 kVp, variable mA, 2.5-mm slice thickness) were identified in 100 patients. The raw CT source data were prospectively reconstructed twice: once using Veo MBIR and once using a blend of 30% adaptive statistical iterative reconstruction (ASiR) and filtered back projection (FBP). Lesions were chosen to form four equal-sized (n = 25) groups stratified by lesion size (10-19 or 20-29 mm) and growth pattern (endophytic or exophytic). Attenuation (in HU) was measured using identical ROIs and compared with two-tailed t tests. The effects of patient diameter and lesion anatomy on attenuation discrepancies of 5 HU or more were assessed using binary logistic regression.
RESULTS: Mean MBIR attenuation was not significantly different than mean 30% ASiR/FBP attenuation in the overall study population (unenhanced phase, 17 ± 13 vs 17 ± 13 HU, p = 0.74; nephrographic phase, 31 ± 27 vs 30 ± 26 HU, p = 0.89) or in any subgroup (p = 0.63-0.95). Only lesion size predicted discrepancies of 5 HU or more (p = 0.008; odds ratio, 1.20 [95% CI, 1.05-1.34] per 1 mm decrease) (p = 0.19-0.98 for the other variables). Seven lesions had enhancement of 20 HU or more with only one reconstruction method (MBIR = 4; 30% ASiR = 3).
CONCLUSION: Veo MBIR has no significant or consistent effect on attenuation measurements within small (10-29 mm) low-attenuation renal masses and is therefore unlikely to change clinically accepted attenuation thresholds for renal mass characterization.